BenevolentAI, today announced that it has appointed Joanna Shields as Group CEO. The appointment reflects the rapid growth of BenevolentAI and will enable the company to build upon its position as the market leader in developing and applying artificial intelligence for scientific discovery. Joanna will join BenevolentAI with immediate effect.
A collaboration between Parkinson's UK and The Cure Parkinson's Trust (CPT) to identify new treatments for Parkinson's has been awarded the inaugural BenevolentAI Award. Presented through a competition run with the Association of Medical Research Charities (AMRC), the award offers a selected charity AI-driven R&D support from BenevolentAI, one of Europe's largest private AI companies.
BenevolentAI and Action Against AMD, a group of UK sight loss charities, have today announced their partnership to use BenevolentAI's technology to find treatments and a potential cure for the leading cause of blindness in the UK - 'age-related macular degeneration' (AMD).
Dr Laura Ferraiuolo, Lecturer in Translational Neurobiology at SITraN in Sheffield and expert in ALS (Amyotrophic Lateral Sclerosis), disease talks about the advancement of research for ALS and the need for researchers to welcome new technologies to help them progress in finding potential new cures.
Ken Mulvany talks to IBT about how the efficiency in the pharmaceutical industry can be increased by integrating AI methods.
One of the largest AI enterprises in the world, BenevolentAI has acquired a research facility in Babraham, FierceBiotech is reporting on it.
Ken Mulvany talks to CityAm about AI, innovations and his ambitions for BenevolentAI
Listen to Jackie Hunter taking part to the BBC podcast with Evan Davis to discuss the relationship between three important pillars of modern society: science, business and the consumer. Is the public right to be suspicious of business and the science it's selling? Why do some us fear GM foods, nanotechnology, AI and gene editing?
BenevolentAI, one of the world’s largest private AI companies, in partnership with the Association of Medical Research Charities (“AMRC”) announced today it has created a new award, the BenevolentAI Award, to help charities accelerate their medical research and potentially develop new treatments and therapies using artificial intelligence.
Read more about the current advancements and innovations made towards finding a cure for ALS (Lou Gehrig’s disease)
WIRED talks to Jackie Hunter about the positive disruption BenevolentAI is bringing to the pharma industry, and the scientific unknowns its helping to unlock using AI.
FierceBiotech covers the news that we have hired Dr Ian Churcher MA, DPhil as VP of Drug Discovery and Preclinical development. Ian joins from GSK where he previously headed up a Discovery Performance Unit.
Our recent work with the Sheffield Institute of Translational Neuroscience (SITraN) on finding treatments for ALS is featured on Reuters UK. BenevolentBio CEO Professor Jackie Hunter and Dr Richard Mead of SITraN are interviewed about the effects of the disease and the process involved in finding the treatments.
Lynsey Barber reports on BenevolentAI office opening in New York
BenevolentAI, one of the world’s largest private AI companies, today announced it is expanding its footprint in the United States by opening an office in New York City and has made two significant hires - Keith Hall, from Google, and Daniel Neil, from the Institute of Neuroinformatics, that will form the foundation of the new New York BenevolentAI team.
Professor Jackie Hunter speaks to the Science Disrupt podcast about the potential to improve the drug discovery process with machine learning, as well as how AI is streamlining science more generally. In addition to opening up the potential for a whole new universe of potential findings, the podcast covers what this means for science as an evidence-based endeavour and whether it can help to reduce publication bias.
Taking a closer look at how big data and machine learning is transforming precision medicine, Adi Gaskell covers our work at BenevolentAI and the partnership with Sheffield Institute for Translational Neuroscience (SITraN) for Motor Neuron Disease research.
We teamed up with Sheffield Institute for Translational Neuroscience (SITraN) to test some of our AI-driven hypotheses in its ALS disease models. Dr Laura Ferraiulo, co-lead on the project from SITraN, spoke to IDG Connect about how this led to a potentially major breakthrough.
Our founder Ken Mulvany features in an article looking at the UK’s growing performance in AI technology and the investment the country’s industry is attracting. Ken speaks to Bloomberg’s Giles Turner about BenevolentAI's hiring spree and the 50 roles we are looking to fill.
Sheffield and London, UK - 25 May 2017. The Sheffield Institute for Translational Neuroscience (SITraN), part of the University of Sheffield and one of the world’s leading centres for research into Motor Neurone Disease, Alzheimer’s and Parkinson’s Disease, today announced that its research into a drug candidate discovered by British artificial intelligence firm BenevolentAI has delivered positive results.
Nanalyze includes BenevolentAI in its round up of computational drug discovery start-ups using AI.
Ken Mulvany, is interviewed by Business Insider UK in an article exploring BenevolentAI’s work to develop new drugs for diseases like Alzheimer’s and ALS.
This week, Pharmaphorum covered our partnership announcement with MRC Technology. We’ve teamed up with the independent research charity to investigate new small molecule and antibody drug candidates, combining our technology and R&D experience with their expertise.
London, 11 April 2017 – BenevolentAI, a British artificial intelligence company, today announced that it has partnered with MRC Technology (“MRCT”), a medical research charity, to explore drug discovery initiatives in the field of small molecules and antibodies.